Omeros (OMER) Receives a Buy from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros (OMERResearch Report) today and set a price target of $35.00. The company’s shares closed last Monday at $13.60.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -15.7% and a 30.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $28.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros has an average volume of 428.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.